Q1 results, resolving litigation, but faces trade and NIH policy challenges. Click for my look at TXG stock prospects.

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated ...

"10x Genomics, Inc. (NASDAQ:TXG) sells products that offer life sciences researchers single cell, spatial, and in-situ views of biological systems. Shares underperformed in the quarter, ...

10x Genomics employed 584 workers worldwide at the end of 2019, 852 people at the end of 2020, 1,239 people at the end of 2021 and 1,243 at the end of 2022, the SEC filings showed.

Genomics startup Parse Biosciences lost its bid to dismiss a patent-infringement lawsuit brought by rival 10x Genomics and Stanford University on Thursday, when a Delaware federal court denied ...

10x Genomics will host a conference call to discuss its third quarter 2024 results, business developments and outlook after market close on Tuesday, October 29, 2024 at 1:30 PM Pacific Time / 4:30 ...

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for. 10x Genomics missed analysts’ revenue expectations by 5% last quarter ...

10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2021 based on publications and all of ...

10x Genomics reported 18% YoY revenue growth in Q4, reaching $184M, with instruments revenue seeing a remarkable surge of 71%. Find out why TXG is poised for sustained growth.

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into a scheduled two-week trial, according to a Thursday filing in Delaware ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly filed against Vizgen Inc. in 2022.